Thursday January 18th 2018

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

US-based biopharmaceutical firm Celgene has reported positive results from the Phase III RADIANCE clinical trial of ozanimod for the treatment of relapsing multiple sclerosis (RMS) patients. (Source: Drug Development Technology)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Link:

Celgene ’s Phase III trial of ozanimod for RMS meets primary endpoint

Leave a Comment

More from category

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]

Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…
Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…

Multiple sclerosis (MS) is a neuroinflammatory condition characterized by chronic dysregulation of immune responses [Read More]

Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity
Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity

Here's what we selected for you today: NEJM Clinical Practice Center: Review: A number of interventions to modify the [Read More]